Calvo, Emiliano
Sessa, Cristiana
Harada, Guilherme
de Miguel, Maria
Kahatt, Carmen
Luepke-Estefan, Xarles Erik
Siguero, Mariano
Fernandez-Teruel, Carlos
Cullell-Young, Martin
Stathis, Anastasios
Drilon, Alexander
Article History
Received: 13 June 2022
Accepted: 3 July 2022
First Online: 10 August 2022
Declarations
:
: The study was approved by the Research Ethics Committees of participating centers in the U.S., Spain and Switzerland. The study was conducted in full accordance with the principles of the World Medical Association Declaration of Helsinki, the International Conference of Harmonisation, and all applicable local guidelines and regulations on good clinical practice.
: Written informed consent was obtained from all individual patients included in this study.
: All patients provided written informed consent about participation in this study and the use of collated data. No individual patient data are included in this article that could be used to identify any individual.
: M. de Miguel reports research funding from MSD, Basilea, Faron, Achilles, Pharmamar, Roche, Regeneron, Nektar, Loxo, Genmab, Cytomex, Bayer, Astra Zeneca, Novartis, Abbvie, Array, Eisai, and Sanofi; and Speaker’s Bureau membership for MSD, Janssen, and Roche; all outside the submitted work. C. Kahatt reports personal fees for salary as full time employee and stock ownership from Pharma Mar, outside the submitted work. X.E. Luepke-Estefan, M. Siguero and M. Cullell-Young report personal fees for salary as full time employee from Pharma Mar, outside the submitted work. C. Fernandez-Teruel was an employee of Pharma Mar at the time the study was carried out. A. Stathis reports institutional grants for clinical trials from Merck, Bayer, Roche, Novartis, Pfizer, ADC Therapeutics, MEI Pharma, Eli Lilly, and Pharma Mar; a consultant position with Bayer, Eli Lilly, Roche, and Novartis; and travel grants from Abbvie and Pharma Mar; all outside the submitted work. A. Drilon reports research grants from Foundation Medicine; associated research grants (paid to institution) from Pfizer, Exelixis, GlaxoSmithKline, Teva, Taiho, and Pharma Mar; an advisory board position with Ignyta/Genentech/Roche, Loxo/Bayer/Lilly, Takeda/Ariad/Millenium, TP Therapeutics, AstraZeneca, Pfizer, Blueprint Medicines, Helsinn, Beigene, BergenBio, Hengrui Therapeutics, Exelixis, Tyra Biosciences, Verastem, MORE Health, Abbvie, 14ner/Elevation Oncology, ArcherDX, Monopteros, Novartis, EMD Serono, Medendi, Repare RX, Nuvalent, Merus, Chugai Pharmaceutical, Remedica Ltd, mBrace, AXIS, EPG Health, Harborside Nexus, Liberum, RV More, Ology, Amgen, TouchIME, Janssen, Entos, Treeline Bio, Prelude, Applied Pharmaceutical Science Inc, I3 Health, AiCME, and MonteRosa; CME honoraria from Medscape, OncLive, PeerVoice, Physicians Education Resources, Targeted Oncology, Research to Practice, Axis, Peerview Institute, Paradigm Medical Communications, WebMD, MJH Life Sciences, Med Learning, Imedex, Answers in CME, Clinical Care Options, EPG Health, JNCC/Harborside, Liberum, and Remedica Ltd.; royalties from Wolters Kluwert; equity from Treeline Bio; copyright from Selpercatinib-Osimertinib (filed/pending); and other support from Merck, Puma, Merus, and Boehringer Ingelheim; all outside the submitted work. No potential conflicts of interest were disclosed by the other authors.